Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Pentosan Polysulfate Sodium (PPS / Elmiron)
Also known as: PPS, Elmiron, Pentosan Polysulfate Sodium, bFGF-stimulating GAG
Confidence
Updated 2026-03-18
Pentosan polysulfate sodium (PPS) is a semi-synthetic heparinoid glycosaminoglycan FDA-approved as Elmiron for interstitial cystitis/bladder pain syndrome. While not a peptide per se, it is widely offered by peptide therapy clinics for its tissue-repair and anti-inflammatory properties, particularly for joint health and osteoarthritis. It has a long clinical track record dating to the 1990s.
Class
Tissue Repair / Glycosaminoglycan
Routes
Oral, Intramuscular, Subcutaneous
Half-Life
~4.8 hours (oral); ~24 hours (subcutaneous/IM in veterinary PK)
PPS coats and restores the damaged glycosaminoglycan (GAG) layer of the bladder urothelium (IC indication). For joint health, it inhibits cartilage-degrading enzymes (MMPs, aggrecanases), stimulates proteoglycan synthesis by chondrocytes, improves synovial fluid viscosity, enhances subchondral blood flow, and exhibits mild anticoagulant and fibrinolytic activity. Also stimulates basic fibroblast growth factor (bFGF) release.
Half-Life
~4.8 hours (oral); ~24 hours (subcutaneous/IM in veterinary PK)
Bioavailability
Oral: ~3–6% (very low); IM/SC: significantly higher (primarily studied in veterinary medicine)
FDA-approved: Interstitial cystitis/bladder pain syndrome. Off-label/research: osteoarthritis, joint repair, chronic pain, bone marrow edema, tendinopathy.
FDA-approved for IC based on clinical trials showing improved bladder pain and urgency. For osteoarthritis, multiple Australian studies (injectable PPS) demonstrated improved pain scores and cartilage markers — an Australian Phase III trial showed significant improvement in knee OA. Veterinary evidence is robust (Adequan for equine/canine OA). Human injectable OA data emerging but not yet FDA-approved for this indication.
Human Studies
40
Animal Studies
60
Oral (Elmiron): Generally well-tolerated. Key concern: pigmentary maculopathy (retinal toxicity) with long-term use — FDA updated labeling in 2020. GI upset, hair loss (rare), mild anticoagulant effect. Injectable: injection site reactions. Retinal monitoring now recommended for chronic oral use.
FDA-approved for IC (oral) since 1996. Injectable formulations available through compounding pharmacies for off-label joint use. Ongoing regulatory discussion regarding retinal safety monitoring requirements.
Drug Interactions: Mild anticoagulant — caution with blood thinners (warfarin, DOACs, aspirin). May potentiate bleeding risk. Monitoring: Ophthalmologic exam (baseline and periodic) for long-term oral use due to maculopathy risk. Joint symptom scores for OA use. Research Gaps: Injectable PPS for OA needs larger Western Phase III trials. Optimal dose and duration for joint indications not established.
Oral (Elmiron, FDA-approved for IC)
Common Range
100 mg three times daily
Timing
On an empty stomach, 1 hour before or 2 hours after meals
Frequency
Three times daily
Cycling
Continuous — reassess at 3–6 months for IC
Important Note
FDA-approved for interstitial cystitis. Retinal monitoring recommended for chronic use. Very low oral bioavailability.
Subcutaneous/IM (off-label, joint health)
Common Range
2 mg/kg twice weekly (based on Australian study protocols)
Timing
Any time
Frequency
Twice weekly for 6 weeks, then reassess
Cycling
6-week induction courses
Important Note
Off-label for joint health. Based on Australian clinical trial protocols and veterinary dosing. Higher bioavailability than oral route.
Connect with a verified provider offering Pentosan Polysulfate therapy near you.
Tissue Repair & Regeneration
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It has generated extraordinary interest for its broad cytoprotective and regenerative effects observed in preclinical studies across virtually every organ system studied. Despite this promise, it remains one of the most controversial peptides due to the near-complete absence of human clinical trial data.
Tissue Repair & Regeneration
TB-500 is a synthetic version of thymosin beta-4, a naturally occurring 43-amino acid protein fragment that plays critical roles in tissue repair, cell migration, and anti-inflammatory processes. Combined with BPC-157, it forms what is colloquially known as "the Wolverine stack" in regenerative wellness circles. Like BPC-157, its clinical evidence base is limited to preclinical data.
Tissue Repair / Anti-Aging
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Levels decline significantly with age (from ~200 ng/mL at age 20 to ~80 ng/mL at age 60). It has gained attention for its broad biological activities including wound healing, anti-inflammatory effects, collagen synthesis, and potential gene expression modulation.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.